Sepsis patients could get the right treatment faster, based on their genes Date: June 18, 2024 Source: Wellcome Trust Sanger Institute Summary: New study into the molecular pathways involved in ...

The REVIVAL study is evaluating AM-Pharma’s proprietary recombinant alkaline phosphatase, ilofotase alfa, for the treatment of patients with sepsis-associated acute kidney injury (SA-AKI).

Using data from Mass General Brigham's electronic health records, Brigham researchers quantified the burden of SARS-CoV-2-associated sepsis early in the pandemic.